Raymond James Reaffirms “Strong-Buy” Rating for Haemonetics (NYSE:HAE)
Raymond James restated their strong-buy rating on shares of Haemonetics (NYSE:HAE – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $105.00 price target on the medical instruments supplier’s stock, down from their previous price target of $115.00. Other equities analysts have also issued research reports about the […]
Raymond James restated their strong-buy rating on shares of Haemonetics (NYSE:HAE – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $105.00 price target on the medical instruments supplier’s stock, down from their previous price target of $115.00. Other equities analysts have also issued research reports about the […]
